FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2594442961> ?p ?o ?g. }

• W2594442961 endingPage "84" @default.
• W2594442961 startingPage "74" @default.
• W2594442961 abstract "γ-Tocotrienol, a vitamin E isomer possesses pronounced in vitro anticancer activities. However, the in vivo potency has been limited by hardly achievable therapeutic levels owing to inefficient high-dose oral delivery which leads to subsequent metabolic degradation. Jerantinine A, an Aspidosperma alkaloid, originally isolated from Tabernaemontana corymbosa, has proved to possess interesting anticancer activities. However, jerantinine A also induces toxicity to non-cancerous cells. We adopted a combinatorial approach with the joint application of γ-tocotrienol and jerantinine A at lower concentrations in order to minimize toxicity towards non-cancerous cells while improving the potency on brain cancer cells. The antiproliferative potency of individual γ-tocotrienol and jerantinine A as well as combined in low-concentration was firstly evaluated on U87MG cancer and MRC5 normal cells. Morphological changes, DNA damage patterns, cell cycle arrests and the effects of individual and combined low-concentration compounds on microtubules were then investigated. Finally, the potential roles of caspase enzymes and apoptosis-related proteins in mediating the apoptotic mechanisms were investigated using apoptosis antibody array, ELISA and Western blotting analysis. Combinatorial study between γ-tocotrienol at a concentration range (0–24 µg/ml) and fixed IC20 concentration of jerantinine A (0.16 µg/ml) induced a potent antiproliferative effect on U87MG cells and led to a reduction on the new half maximal inhibitory concentration of γ-tocotrienol (i.e. tIC50 = 1.29 µg/ml) as compared to that of individual γ-tocotrienol (i.e. IC50 = 3.17 µg/ml). A reduction on undesirable toxicity to MRC5 normal cells was also observed. G0/G1 cell cycle arrest was evident on U87MG cells receiving IC50 of individual γ-tocotrienol and combined low-concentration compounds (1.29 µg/ml γ-tocotrienol + 0.16 µg/ml jerantinine A), whereas, a profound G2/M arrest was evident on cells treated with IC50 of individual jerantinine A. Additionally, individual jerantinine A and combined compounds (except individual γ-tocotrienol) caused a disruption of microtubule networks triggering Fas- and p53-induced apoptosis mediated via the death receptor and mitochondrial pathways. These findings demonstrated that the combined use of lower concentrations of γ-tocotrienol and jerantinine A induced potent cytotoxic effects on U87MG cancer cells resulting in a reduction on the required individual concentrations and thereby minimizing toxicity of jerantinine A towards non-cancerous MRC5 cells as well as probably overcoming the high-dose limiting application of γ-tocotrienol. The multi-targeted mechanisms of action of the combination approach have shown a therapeutic potential against brain cancer in vitro and therefore, further in vivo investigations using a suitable animal model should be the way forward." @default.
• W2594442961 created "2017-03-16" @default.
• W2594442961 creator A5019235752 @default.
• W2594442961 creator A5026845999 @default.
• W2594442961 creator A5034563250 @default.
• W2594442961 creator A5062083026 @default.
• W2594442961 date "2017-07-01" @default.
• W2594442961 modified "2023-10-06" @default.
• W2594442961 title "Enhancement of apoptotic activities on brain cancer cells via the combination of γ-tocotrienol and jerantinine A" @default.
• W2594442961 cites W1820554624 @default.
• W2594442961 cites W1965309927 @default.
• W2594442961 cites W1966630972 @default.
• W2594442961 cites W1984523462 @default.
• W2594442961 cites W1989604654 @default.
• W2594442961 cites W2007209086 @default.
• W2594442961 cites W2007458878 @default.
• W2594442961 cites W2008757142 @default.
• W2594442961 cites W2012654782 @default.
• W2594442961 cites W2013837833 @default.
• W2594442961 cites W2020994403 @default.
• W2594442961 cites W2023356591 @default.
• W2594442961 cites W2028426028 @default.
• W2594442961 cites W2029134404 @default.
• W2594442961 cites W2029906657 @default.
• W2594442961 cites W2049062689 @default.
• W2594442961 cites W2061448159 @default.
• W2594442961 cites W2078291699 @default.
• W2594442961 cites W2085566479 @default.
• W2594442961 cites W2103023937 @default.
• W2594442961 cites W2103562758 @default.
• W2594442961 cites W2115535498 @default.
• W2594442961 cites W2135924782 @default.
• W2594442961 cites W2153127376 @default.
• W2594442961 cites W2159760706 @default.
• W2594442961 cites W2274743308 @default.
• W2594442961 cites W2289145932 @default.
• W2594442961 doi "https://doi.org/10.1016/j.phymed.2017.03.004" @default.
• W2594442961 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28545672" @default.
• W2594442961 hasPublicationYear "2017" @default.
• W2594442961 type Work @default.
• W2594442961 sameAs 2594442961 @default.
• W2594442961 citedByCount "19" @default.
• W2594442961 countsByYear W25944429612018 @default.
• W2594442961 countsByYear W25944429612019 @default.
• W2594442961 countsByYear W25944429612020 @default.
• W2594442961 countsByYear W25944429612021 @default.
• W2594442961 countsByYear W25944429612022 @default.
• W2594442961 countsByYear W25944429612023 @default.
• W2594442961 crossrefType "journal-article" @default.
• W2594442961 hasAuthorship W2594442961A5019235752 @default.
• W2594442961 hasAuthorship W2594442961A5026845999 @default.
• W2594442961 hasAuthorship W2594442961A5034563250 @default.
• W2594442961 hasAuthorship W2594442961A5062083026 @default.
• W2594442961 hasConcept C121608353 @default.
• W2594442961 hasConcept C178790620 @default.
• W2594442961 hasConcept C185592680 @default.
• W2594442961 hasConcept C190283241 @default.
• W2594442961 hasConcept C202751555 @default.
• W2594442961 hasConcept C207001950 @default.
• W2594442961 hasConcept C2777551382 @default.
• W2594442961 hasConcept C2777752497 @default.
• W2594442961 hasConcept C2778004101 @default.
• W2594442961 hasConcept C2778310972 @default.
• W2594442961 hasConcept C2781449162 @default.
• W2594442961 hasConcept C29537977 @default.
• W2594442961 hasConcept C29730261 @default.
• W2594442961 hasConcept C54355233 @default.
• W2594442961 hasConcept C55493867 @default.
• W2594442961 hasConcept C57992300 @default.
• W2594442961 hasConcept C86803240 @default.
• W2594442961 hasConcept C96232424 @default.
• W2594442961 hasConcept C98274493 @default.
• W2594442961 hasConceptScore W2594442961C121608353 @default.
• W2594442961 hasConceptScore W2594442961C178790620 @default.
• W2594442961 hasConceptScore W2594442961C185592680 @default.
• W2594442961 hasConceptScore W2594442961C190283241 @default.
• W2594442961 hasConceptScore W2594442961C202751555 @default.
• W2594442961 hasConceptScore W2594442961C207001950 @default.
• W2594442961 hasConceptScore W2594442961C2777551382 @default.
• W2594442961 hasConceptScore W2594442961C2777752497 @default.
• W2594442961 hasConceptScore W2594442961C2778004101 @default.
• W2594442961 hasConceptScore W2594442961C2778310972 @default.
• W2594442961 hasConceptScore W2594442961C2781449162 @default.
• W2594442961 hasConceptScore W2594442961C29537977 @default.
• W2594442961 hasConceptScore W2594442961C29730261 @default.
• W2594442961 hasConceptScore W2594442961C54355233 @default.
• W2594442961 hasConceptScore W2594442961C55493867 @default.
• W2594442961 hasConceptScore W2594442961C57992300 @default.
• W2594442961 hasConceptScore W2594442961C86803240 @default.
• W2594442961 hasConceptScore W2594442961C96232424 @default.
• W2594442961 hasConceptScore W2594442961C98274493 @default.
• W2594442961 hasFunder F4320321709 @default.
• W2594442961 hasLocation W25944429611 @default.
• W2594442961 hasLocation W25944429612 @default.
• W2594442961 hasOpenAccess W2594442961 @default.
• W2594442961 hasPrimaryLocation W25944429611 @default.
• W2594442961 hasRelatedWork W1997949901 @default.
• W2594442961 hasRelatedWork W2019700826 @default.

• next